TScan Therapeutics, Inc.
TCRXNASDAQHealthcare● Active
$0.99
+$0.01(+1.22%)
Market Cap$60701676
P/E Ratio—
52W High$2.57
52W Low$0.882
TScan Therapeutics, Inc. (TCRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TCRX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $10.32M | $2.82M | $21.05M | $13.54M | $10.14M |
| Cost of Revenue | $2.87M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $7.46M | $2.82M | $21.05M | $13.54M | $10.14M |
| Gross Margin %(computed) | 72.24% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $114.15M | $107.35M | $88.15M | $59.82M | $44.95M |
| G&A Expenses | $31.99M | $29.56M | $25.49M | $20.35M | $13.83M |
| Total Operating Expenses | $143.27M | $137.64M | $114.51M | $80.17M | $58.78M |
| Operating Income | ($135.81M) | ($134.82M) | ($93.46M) | ($66.64M) | ($48.64M) |
| Operating Margin %(computed) | — | — | -444.00% | -492.32% | -479.65% |
| Interest Income | $8.82M | $12.06M | $8.00M | $1.59M | $0.02M |
| Interest Expense | $2.77M | $3.65M | $3.76M | $1.18M | $0.00M |
| Income Before Tax | ($129.77M) | ($127.50M) | ($89.22M) | ($66.22M) | ($48.63M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($129.77M) | ($127.50M) | ($89.22M) | ($66.22M) | ($48.63M) |
| Net Margin %(computed) | — | — | -423.86% | -489.26% | -479.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.00 | $-1.14 | $-1.36 | $-2.74 | $-2.03 |
| Wtd Avg Shares | 129.86M | 111.99M | 65.60M | 24.05M | 23.91M |
| EBITDA | ($132.95M) | ($119.74M) | ($80.10M) | ($59.91M) | ($45.30M) |
| EBITDA Margin %(computed) | — | — | -380.53% | -442.62% | -446.67% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more TScan Therapeutics, Inc. data
About TScan Therapeutics, Inc. (TCRX) Income Statement
TScan Therapeutics, Inc. (TCRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TCRX reported revenue of $0.01B, gross profit of $0.01B (gross margin 72.24%), and net income of ($0.13B) — a net profit margin of -1256.81%.
Frequently asked questions
TCRX · 4 questionsTScan Therapeutics, Inc. (TCRX) reported revenue of $0.01B for 2025, up 266.7% year-over-year.
TCRX revenueTCRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09